The mammalian serine/threonine protein kinase D (PKD)[^1^](#G1){ref-type="fn"} family comprises three different but closely related serine kinases, PKD1, PKD2, and PKD3 all of which have a highly conserved N-terminal regulatory domain containing two cysteine-rich diacylglycerol (DAG) binding domains ([@B1]). T lymphocytes express high levels of PKD2 and this kinase is selectively activated by the T-cell antigen receptor (TCR). The activation of PKD2 is initiated by DAG binding to the PKD N terminus but is also critically dependent on Protein kinase C (PKC)-mediated phosphorylation of two serine residues (Ser707 and Ser711) within the activation loop of the PKD2 catalytic domain ([@B2], [@B3]). The importance of PKD2 for T-cell function has been probed by experiments in mice that lack expression of catalytically active PKD2. These studies have shown that PKD2 is important for effector cytokine production after T-cell antigen receptor engagement and also for optimal induction of T-cell dependent antibody responses ([@B4], [@B5]). PKD2 thus has a key role in adult mice to control the function of T cells during adaptive immune responses.

The importance of PKD2 for primary T-cell function makes it critical to understand how PKD2 controls protein phosphorylation pathways. In this context, experiments with constitutively active and dominant negative PKD mutants in tissue culture cell lines have identified a number of candidate PKD substrates. These include the protein phosphatase Slingshot ([@B6], [@B7]), the Ras effector Rin1 ([@B8]), phosphatidylinositol-4 kinase III beta ([@B9]), lipid and sterol transfer proteins such as CERT and OSBP ([@B10], [@B11]). There are also experiments that have identified a key role for PKDs in regulating the phosphorylation and subcellular localization of the class II histone deacetylases (HDACs). For example, in PKD null DT40 B cell lymphoma cells the B cell antigen receptor cannot induce the phosphorylation and nuclear exclusion of the class II HDACs, HDAC5 and 7 ([@B12]). However, it remains to be determined whether the documented PKD substrates are universal PKD substrates in different cell lineages. In this context, the intracellular localization of PKD isoforms varies in different cells ([@B13]), and PKDs have also been shown to traffic between different cellular locations in response to specific stimuli ([@B2], [@B14]). PKD function is dependent on its localization and cell context presumably reflecting that the localization of PKDs plays a key role determining the nature of PKD substrates in different cell populations ([@B15]).

Recently, mass-spectrometry based quantitative phosphoproteomics has been used to explore serine/threonine kinase controlled signaling pathways in T cells ([@B16][@B17]--[@B18]). In this regard, SILAC labeling combined with quantitative mass-spectrometry has recently been used to examine the impact of overexpressing active and/or kinase dead PKD1 mutants in HEK293 cells treated with nocodazole, a microtubule-depolymerizing reagent that disrupts the Golgi complex and activates PKD1 ([@B19]). This has identified a number of PKD1 substrates in HEK293 cells. PKD1 and PKD2 are highly homologous kinases but it remains to be determined whether the PKD1 substrates identified in nocodazole-treated HEK293 cells are relevant to signaling pathways controlled by endogenous PKD2 in antigen receptor activated primary T cells.

Accordingly, in the present study we used SILAC labeling combined with phosphopeptide enrichment and mass-spectrometry quantification to compare the phosphoproteome of antigen receptor activated wild type and PKD2 deficient cytotoxic T cells (CTLs). Our experiments identify and quantify more than 15,000 site-specific phosphorylations in antigen receptor activated CTLs and thus provide a unique data source about the signaling networks operational in these cells. The loss of PKD2 impacts on about 5% of these phosphorylations and reveals that PKD2 has both positive and negative regulatory roles in regulating protein phosphorylation networks in T cells.

EXPERIMENTAL PROCEDURES
=======================

### 

#### Mice, Cell Culture, and SILAC Labeling

P14 T-cell receptor transgenic mice (P14-TCR) PKD2 null mice ([@B4], [@B5]), and wild-type littermates were bred and maintained under specific pathogen-free conditions in the Wellcome Trust Biocenter at the University of Dundee in compliance with U.K. Home Office Animals (Scientific Procedures) Act 1986 guidelines as previously describe ([@B17], [@B20]). P14 CTL were generated and labeled in SILAC media as previously described ([@B17]). Briefly, splenocytes were activated for 2 days with the P14-TCR cognate ligand (peptide gp33--41 from Lymphocytic Choriomeningitis Virus, LCMV). Then, cells were cultured for 4 days in SILAC medium (Dundee Cell Products, Dundee, UK), [l]{.smallcaps}-proline 200 mg/l, [l]{.smallcaps}-arginine 84 mg/l, pre-supplemented with 300 mg/l [l]{.smallcaps}-glutamate, 10% dialyzed FCS with a 10kDa cutoff (Invitrogen, Carlsbad, CA), 50 units/ml penicillin-G, 50 μg/ml streptomycin and 50 μ[m]{.smallcaps} β-mercaptoethanol, and 20 ng/ml IL-2 (Proleukin, Novartis, Basel, Switzerland). The following arginine and lysine isotopes were used: The SILAC labeling was performed in three biological replicates, where the P14 wild-type CTLs cells comprised the "light" condition and PKD2 null CTLs were labeled with "heavy" amino acids in two experiments (experiments 1 and 2), and a label switch was performed in the third experiment (experiment 3).

For the generation of non-TCR transgenic CTLs, splenocytes were activated for 2 days with 0.5 μg/ml of anti-CD3 antibody (2C11, R&D Systems, Minneapolis, MN), followed by 4 days of culture in RPMI (Life Technologies), 10% FCS (Invitrogen), supplemented with penicillin-G, streptomycin, β-mercaptoethanol, and IL-2.

#### Sample Preparation, Phosphopeptide Enrichment, and Mass Spectrometry

P14 wild-type and PKD2 null CTLs differentially labeled in SILAC media for 4 days were mixed at 1:1 ratio (total 3 × 10^8^ cells) and stimulated for 5 min with P14-TCR cognate peptide (LCMV gp33--41). After TCR stimulation, cells were washed once in cold PBS and were subjected to cytosol and nuclear fractionation as previously described ([@B17]). Briefly, cells were resuspended in hypotonic lysis buffer (10 m[m]{.smallcaps} HEPES, pH 7.9, 15 m[m]{.smallcaps} KCl, 4 m[m]{.smallcaps} MgCl~2~, 0.1 m[m]{.smallcaps} EDTA, 10 m[m]{.smallcaps} NaF, 0.15% (v/v) Nonidet-P40, 1 m[m]{.smallcaps} phenylmethylsulfonyl fluoride, 1 m[m]{.smallcaps} Na3VO4, and 1 m[m]{.smallcaps} dithiothreitol) and centrifuged for 1 min at 10,000 × g. Cytosolic fractions were removed and nuclear-membrane fractions were resuspended in nuclear lysis buffer (10 m[m]{.smallcaps} Tris, pH 7.05, 50 m[m]{.smallcaps} NaCl, 30 m[m]{.smallcaps} sodium pyrophosphate, 50 m[m]{.smallcaps} NaF, 5 m[m]{.smallcaps} ZnCl2, 10% (v/v) glycerol, and 0.5% (v/v) Triton-X100). Cytosolic and nuclear fractions were precipitated with trichloroacetic acid (10%, v/v) for 15 min/ice. Protein pellets were resuspended in Urea 8 [m]{.smallcaps} Tris-HCl 100 m[m]{.smallcaps}. Cytosolic and nuclear lysates were subjected to alkylation with iodoacetamide prior to trypsin digestion (Roche, Basel, Switzerland).

#### Hydrophilic Liquid Interaction Chromatography (HILIC), Immobilized Metal Ion Affinity Chromatography (IMAC), and Titanium Dioxide (TiO~2~) Affinity Chromatography

Proteolytic digestion products were desalted on a 1-g Sep-Pak cartridge (Waters, Milford, MA), and subjected to hydrophilic interaction liquid chromatography (HILIC) using a 4.6 × 250-mm TSKgel Amide-80 5-μm particle column (Tosoh Biosciences, Tokyo, Japan). The following buffers were used: HILIC buffer A (0.1% TFA) and HILIC buffer B (99.9% acetonitrile and 0.1% TFA). The peptide pellets were resuspended in 80% HILIC buffer B and injected onto the HILIC column. The chromatography was done using the following elution gradient: 80% B held for 20 min followed by 80% B to 60% B in 40 min and finally 0% B for 10 min.

Eighteen fractions of each subcellular compartment were collected throughout the gradient and further enriched in phosphopeptides by immobilized metal affinity chromatography (IMAC, Phos-Select, Sigma) following manufacturer\'s instructions. Peptides were eluted with 200 μl, 0.4 [m]{.smallcaps} NH4OH followed with 200 μl, 0.2 [m]{.smallcaps} NH4OH/50% acetonitrile. A gel-loading tip was used to remove elution fractions and further remaining IMAC beads were removed by passing fractions through a ZipTip (Millipore). The supernatants from the IMAC (combining the 18 fractions for each subcellular compartment in nine samples) were used for additional TiO~2~ pull down (Titanspheres, GL Sciences, Shinjuku, Japan).

#### Liquid Chromatography - Mass Spectrometry (LC-MS)

The peptide mixture was separated by nanoscale C18 reverse-phase liquid chromatography (Ultimate 3000 nLC (Dionex, Sunnyvale, CA) coupled online to a Linear Trap Quadrupole (LTQ)-Orbitrap mass spectrometer (LTQ-Orbitrap Velos; Thermo Fisher Scientific). The following buffers were used: HPLC Buffer A (2% acetonitrile and 0.01% formic acid), HPLC Buffer B (90% acetonitrile and 0.08% formic acid) and HPLC Buffer C (0.05% trifluoroacetic acid). Samples were injected in 1% formic acid, washed onto the column with HPLC Buffer C and eluted with a flow of 0.3 μl/min under usage of the following buffer gradient: 5% B (0--3 min), 5--35% B (3--68 min), 35--90% B (68--70 min), 90% B (70--80 min), 90--5% B (80--81 min), and equilibrated in 5% B (81--100 min). The eluting peptide solution was automatically (online) electrosprayed into the mass spectrometer using a nanoelectrospray ion source (Proxeon Biosystems, Odense, Denmark). The mass spectrometers were operated in positive ion mode and used in data-dependent acquisition modes. A full scan (FT-MS) was acquired at a target value of 1,000,000 ions with resolution *r* = 60,000 over a mass range of 335--1800 amu (atomic mass unit). The ten most intense ions were selected for fragmentation in the LTQ Orbitrap Velos. Fragmentation in the LTQ was induced by collision-induced dissociation (CID) with a target value of 10,000 ions. For accurate mass measurement, the "lock mass" function (lock mass = 445.120036 Da) was enabled for MS scan modes. To improve the fragmentation of phosphopeptides, the multistage activation algorithm in the Xcalibur software was enabled for each MS/MS spectrum using the neutral loss values of 48.99, 32.66, and 24.50 *m/z* units. Former target ions selected for MS/MS were dynamically excluded for 300 s. General mass spectrometric conditions were as follows: spray voltage, 1.0--2.5 kV; no sheath and auxiliary gas flow; ion transfer tube temperature, 150--180 °C; and normalized collision energy (35%) using wide band activation mode for MS2. The isolation width was set to 2 amu for IT-MS/MS. Ion selection thresholds were 600 counts for MS2. An activation of q = 0.25 and activation time of 30 ms were applied in MS2 acquisitions. The fill time for FTMS was set to 1000 ms and for ITMS to 150 ms. In this study, three independent biological replicates of P14 wild-type *versus* PKD2 knockout CTLs were analyzed, with two technical replicates for each biological sample (total 310 HPLC-MS/MS runs). In two experiments, the wild-type cells comprised the "light" condition, whereas the PKD2 knockout CTLs were labeled with "heavy" amino acids (experiments 1 and 2). In the third experiment, we performed a label switch (experiment 3).

#### Data Processing

For data analysis, we combined the raw data obtained from the two technical replicates, the two subcellular fractions (nucleus and cytosol), and the IMAC and TiO~2~ phosphopeptide enrichment methods in each independent replicate. Data was processed using MaxQuant ([@B21]) version 1.3.0.5 which incorporates the Andromeda search engine ([@B22]). Proteins were mapped to the Uniprot mouse protein database ("Mouse Complete Proteome" retrieved on August 19, 2013). This version of the database contains 16,618 mouse complete proteome entries (UniProtKB/Swiss-Prot canonical and isoform sequence data). Search parameters specified an MS tolerance of 20 ppm, an MS/MS tolerance at 0.5 Da and full trypsin specificity, allowing for up to two missed cleavages. Carbamidomethylation of cysteine was set as fixed modification and oxidation of methionines, N-terminal protein acetylation, and phosphorylation of serine, threonine, and tyrosine were set as variable modifications. Peptides were required to be at least six amino acids in length with false discovery rates (FDRs) of 0.01 calculated at the level of peptides, proteins, and modification sites based on the number of hits against the reversed sequence database.

To make our data accessible to the scientific community, the MS proteomics data have been deposited to the ProteomeXchange Consortium (<http://proteomecentral.proteomexchange.org>) via the PRIDE partner repository ([@B23]) with the data set identifier PXD001076. The annotated_spectra.zip file contains .pdf files with annotated MS/MS spectra for all PTM containing peptides described in the manuscript. Separate MS/MS spectra for the highest identification and localization scores have been deposited. To facilitate the search for the annotated spectra, an additional excel file (Phospho (STY)Sites_annotated_spectra.xlsx file) containing a list of all reported sites and the file names of their corresponding .pdf files have been deposited. Prior to statistical analysis, the outputs from MaxQuant were filtered to remove known contaminants and reverse sequences. The distribution of SILAC ratios was normalized within MaxQuant at the peptide level so that the median of log~2~ ratios is zero ([@B21]) ([supplemental Table S1](http://www.mcponline.org/cgi/content/full/M113.037242/DC1)).

#### Bioinformatics and Statistical Tools

For functional pathway analysis, the different subsets of proteins identified in the data set were subjected to functional analysis using DAVID bioinformatics resources ([@B24]). Gene ontology terms for biological processes (BP) and molecular functions (MF) charts were obtained using default statistical parameters (threshold: count 2, ease 0.1). Proteins with protein kinase activity and transcription factor activity were filtered based on GOTERM_MF_FAT (GO:0004672 and GO:0003700, respectively).

For the kinase motif distribution, Linear Motif analysis tool in Perseus v1.4.1.3 software was used. Significance of PKD2 motif enrichment was assessed by Chi-square test using Graphpad software (<http://www.graphpad.com/>).

#### Western Blotting

Protein expression was assessed using standard Western blotting protocols described elsewhere ([@B5]). Blots were probed with rabbit polyclonal anti-phospho-Cofilin-Ser3 and anti-Cofilin (Cell Signaling Technology, Danvers, MA), a rabbit polyclonal antisera recognizing HDAC7 (H-273, Santa Cruz Biotechnology, Santa Cruz, CA), or a mouse monoclonal anti-Erk1/2 antibody (3A7, Cell Signaling Technology) as indicated. Horseradish-peroxidase couple anti-rabbit and anti-mouse antibodies were purchased from Jackson Immunoresearch, West Grove, PA.

#### Retroviral Transduction, Confocal Microscopy, and Flow Cytometry

GFP-HDAC7 retrovirus was produced and P14 wild-type and PKD2 deficient CTLs were transduced as described ([@B17], [@B25]). Cells were adhered to coverslips coated with poly-l-lysine (Sigma-Aldrich), then fixed for 30 min at 25 °C with 4% (w/v) paraformaldehyde. A Zeiss LSM700 confocal microscope with an alpha Plan-FLUAR 100× objective (numerical aperture, 1.45) was used for confocal microscopy. For flow cytometry analysis, cells were stained as described ([@B5]). Fluorescein isothiocyanate-anti-CD8 (clone 53--6.7), phycoerythrin-anti-CD5 (clone 53--7.3) and allophycocianine-anti-CD25 (clone PC61) were purchased from BD Pharmingen. Data were acquired on a FACSCalibur (Becton Dickinson) and were analyzed with FlowJo software (Treestar, Ashland, OR).

RESULTS
=======

### 

#### The CTL Phosphoproteome

The present screen used SILAC-based quantitative phosphoproteomic analysis to characterize the kinase-substrate signaling networks present in antigen receptor activated cytotoxic T cells (CTL). SILAC labeling requires that cells undergo multiple cell doublings to ensure sufficient label penetrance. Accordingly, for SILAC experiments in CD8 T cells we used a well-characterized model of CD8 CTL differentiation ([@B17]). In this model, antigen primed CD8^+^ T cells from P14 TCR transgenic mice are cultured in interleukin 2 (IL-2) to produce a homogenous population of fully differentiated effector CTL ([@B20], [@B26], [@B27]). This model reproduces the *in vivo* situation where sustained IL-2 signaling promotes the production of terminally differentiated effector CTLs required for virus clearance ([@B28][@B29]--[@B30]). The impact of loss of the serine-threonine kinase PKD2 on CTL signaling networks was also explored. Hence, in these experiments wild-type or PKD2 knockout P14-TCR CTLs were differentially labeled with one of two different isotope combinations of lysine (K) and arginine (R), R0K0 ("light") and R10K8 ("heavy"). After 4 days of culture in SILAC media, wild-type and PKD2 knockout CTLs were mixed at equal cell number and triggered via their TCR with cognate peptide for 5 min to maximally activate PKD2 in the wild-type population. Cells were then lysed, digested with trypsin and phosphopeptides were enriched by HILIC fractionation followed by IMAC and TiO~2~ affinity chromatography. The workflow of our experiments is displayed in [Fig. 1](#F1){ref-type="fig"}*A*. The phosphopeptide-enriched fractions were analyzed in a LTQ-Orbitrap Velos for mass spectrometry (MS) data collection. All raw mass spectrometry data from three biological replicates were processed using the MaxQuant software.

![**Global phosphoproteomic analysis of PKD2 deficient CTLs.** *A*, Experimental workflow. *B*, Number of unique phosphosites (p-site) and number of distinct proteins identified and quantified in the three individual biological replicates. *C*, Percentage and numbers of unique phosphosites (p-sites) identified in all three biological replicates. *D*, Graph represents the statistical significance (*p value*) of the biological processes overrepresented within the CTL phosphoproteome. Inset numbers indicate number of proteins in each group. *E*, Pie chart represents the frequency of kinases predicted to be active in CTLs.](zjw0121449220001){#F1}

A key aim of this study was to map the repertoire of protein phosphorylations in CTLs. The collective analysis of the current experiments identified and quantified 15,871 unique phosphorylation sites in CTLs on 3505 distinct proteins. The full list of all unique phosphosites identified in our analysis can be found in [supplemental Table S1](http://www.mcponline.org/cgi/content/full/M113.037242/DC1). The ratio of phosphorylations on Serine, Threonine, and Tyrosine residues was 81/17/2, comparable to what has been observed in other phosphoproteomic studies ([@B31], [@B32]). Importantly, the total number of phosphosites identified in the individual biological replicates was similar ([Fig. 1](#F1){ref-type="fig"}*B*), and ∼58% of the unique phosphosites (9205 on 2767 proteins) were identified in all three replicates ([Fig. 1](#F1){ref-type="fig"}*C*). We have previously described a phosphoproteomic analysis of CTLs but these earlier experiments only identified 2000 phosphorylations in CTLs ([@B17]). The higher coverage obtained in the present set of experiments offers a more complete view of CTL signaling networks.

We used DAVID Bioinformatics Resources 6.7 ([@B24]) to perform functional pathway analysis on the phosphoproteins and found that the CTL phosphoproteome is significantly overrepresented by proteins that control gene transcription and chromatin and by kinases and phosphatases that control protein phosphorylation ([Fig. 1](#F1){ref-type="fig"}*D*). There was also overrepresentation in the CTL phosphoproteome of molecules that regulate macromolecular catabolic processes, notably proteins that control the ubiquitylation and sumoylation of proteins ([Fig. 1](#F1){ref-type="fig"}*D*). The mouse genome encodes over 500 protein kinases ([@B33]). The present data detected phosphopeptides from ∼200 protein kinases in CTLs ([supplemental Table S2](http://www.mcponline.org/cgi/content/full/M113.037242/DC1)). We have also used Linear Motif analysis tool in Perseus software to assign the kinases most likely to phosphorylate the 15,871 phosphosites identified in CTLs. This work indicated activity of a minimum of 54 serine/threonine kinases and eight tyrosine kinases in CTLs ([Fig. 1](#F1){ref-type="fig"}*E*). One limitation of this latter analysis is that is difficult to assign substrates individually to closely related kinase isoforms that may share substrate specificity. For example, a proportion of the identified phosphosites in CTLs was predicted to be phosphorylated by Protein Kinase A (PKA) or Protein Kinase C (PKC) ([Fig. 1](#F1){ref-type="fig"}*E*). These are members of the AGC family of kinases and it is very likely that substrates assigned to PKA or PKC may in fact be phosphorylated by other AGC kinases. In this context, the present data reveals the full repertoire of AGC kinase isoforms expressed in CTLs. For example, five of the possible nine Protein Kinase C isoforms were detected in CTLs, PKCα β, δ, PKCη, and PKCθ ([Table I](#TI){ref-type="table"}). The data presented in [Table I](#TI){ref-type="table"} show that AGC kinases in CTL also include two of the four RSK isoforms, RSK1 and RSK2; two of the three Akt isoforms, Akt1 and Akt2; one of the three serum glucocorticoid kinases, SGK3, and one of the two possible S6K isoforms, S6K1. In a similar way, the kinase prediction analysis also indicated activity of the adenosine monophosphate (AMP)-activated protein kinase in CTL ([Fig. 1](#F1){ref-type="fig"}*E*). It is known that CTL are dependent for their survival on LKB1 ([@B34]), which phosphorylates and activates AMPKα1, AMPKα2, and 13 other AMPK-related kinases (AMPK-RK) ([@B35]). The deletion of AMPKα1 does not phenocopy the loss of LKB1 in T cells indicating that it must be other AMPK family members that mediate LKB1 actions ([@B36]). The present data identify the candidates to mediate LKB1 function in T cells, because CTLs express multiple AMPK family isoforms apart from AMPKα1 notably SNRK; SIK1 and 3, and MARK2, 3, and 4 ([Table I](#TI){ref-type="table"}). The data presented in [Table I](#TI){ref-type="table"} and [supplemental Table S2](http://www.mcponline.org/cgi/content/full/M113.037242/DC1) identifying the specific kinase isoforms expressed in CTLs offer invaluable knowledge in the context of the selection of isoform-specific inhibitors of kinase activity and the development of new inhibitors targeting T-cell function.

###### AGC family and AMPK related kinases in CTLs. List of AGC and AMPK-related kinase family members identified in the CTL phosphoproteome

  Kinase family          Kinase   Isoforms present in CTLs
  ---------------------- -------- --------------------------
  AGC                    PDK1     PDK1/*Pdpk1*
                         PKC      PKCα/*Prkca*
                                  PKCb/*Prkcb*
                                  PKCθ/*Prkcq*
                                  PKCη/*Prkch*
                                  PKCδ/*Prkcd*
                         PKN      PNK1/*Pnk1*
                                  PNK2/*Pnk2*
                         Akt      Akt1/*Akt1*
                                  Akt2/*Akt2*
                         S6K      S6K1/*Rps6kb1*
                         RSK      RSK1/*Rps6ka1*
                                  RSK2/*Rps6ka3*
                         SGK      SGK3/*Sgk3*
                         PKA      PKAa/*Prkaca*
                                  PKAb/*Prkacb*
                         MSK      Msk1/*Rps6ka5*
                                  Msk2/*Rps6ka4*
  AMPK related kinases   AMPK     AMPKa1/*Prkaa1*
                         SNRK     SNRK/*Snrk*
                         SIK      SIK1/*Sik1*
                                  SIK3/*Sik3*
                         MARK     MARK2/*Mark2*
                                  MARK3/*Mark3*
                                  MARK4/*Mark4*

The relevance of kinase-substrate networks present in CTLs relies in their ability to dictate the transcriptional program controlling T-cell effector function during an immune response. Accordingly, the most overrepresented function among phosphorylated proteins in CTLs is the regulation of transcription ([Fig. 1](#F1){ref-type="fig"}*D*). Of the 160 proteins with annotated transcription factor activity identified in our data set ([supplemental Table S3](http://www.mcponline.org/cgi/content/full/M113.037242/DC1)), we found relevant phosphorylation sites that regulate transcriptional activity, subcellular localization, and/or protein stabilization of essential transcription factors for CTL development such as the STAT family members STAT3, STAT4, and STAT5, Foxo1, Foxo3, or Myc ([Table II](#TII){ref-type="table"}). More importantly, we identify phosphorylation sites in key transcription factors such as Eomes, T-bet, Hif1α, Arnt, Tfeb, Srebf1, and Srebf2 or Irf4 whose function has not been yet characterized ([Table II](#TII){ref-type="table"}). Notably, several of the phosphosites found for these transcription factors are predicted to be phosphorylated by kinases known to be active in antigen stimulated T cells such as Erk1/2, GSK3, or PKC family ([Table II](#TII){ref-type="table"} and [supplemental Table S3](http://www.mcponline.org/cgi/content/full/M113.037242/DC1)). These data thus open the door for novel targeted approaches exploring the role of protein phosphorylation in regulating CTL transcriptional program.

###### Phosphosites in relevant CTL transcription factors. Identified phosphosites in selected transcription factors known to be essential for CTLs differentiation and function, presented as gene name and modified position (Mod. Pos.)

  Gene name   Mod. Pos.
  ----------- ------------------------------------------------------------
  *Stat3*     S701; Y705; T714; T716; S727
  *Stat4*     S714; S716; S722; S714; S716; S722
  *Stat5a*    S127; S128; Y694; S773; S779; S791
  *Stat5b*    S127; S128; Y699; S127; S128; Y699
  *Foxo1*     S253; S284; S287; S295; S326; T330; S429; T464; S465; S467
  *Foxo3*     S7; S12; S252; T260; S279; S285; S293; S296; S424
  *Myc*       T58; S62; S64; S71; S73; Y74; S160; S164; S282; S288; S293
  *Eomes*     S52; S117; S617; S667; S672; S676
  *Tbx21*     S498; S506; S508; S514
  *Hif1a*     S450; S679
  *Arnt*      S45; S77; S82; S83
  *Tfeb*      S108; S113; S121; S333; S465; S466
  *Srebf1*    S96; S100
  *Srebf2*    S458
  *Irf4*      S186; T435; T436; S446; S447

#### Impact of PKD2 Deficiency on the Cytotoxic T-cell Phosphoproteome

A second aim of the present screen was to use SILAC-based quantitative phosphoproteomic analysis to explore the role of PKD2 in CTLs. The present data reveal that antigen activated CTLs have high levels of active PKD2. We found eight unique phosphosites derived from PKD2 in wild-type CTLs including peptides corresponding to phosphorylated residue Ser711 ([Table III](#TIII){ref-type="table"}). This phosphorylation is mediated by PKCs and is critical for PKD2 catalytic activity ([@B4]). When active, PKD2 autophosphorylates on Ser873 ([@B37]); the presence of phosphorylated PKD2-Ser873 in CTLs thus confirms the activity of this kinase in these cells ([Table III](#TIII){ref-type="table"}). Importantly, the SILAC ratio for all the phosphosites found for PKD2 was down-regulated in PKD2 deficient CTLs, particularly the C-terminal phosphosites ([Table III](#TIII){ref-type="table"}). Previous studies have indicated that T cells do not express PKD1 and only express low levels of PKD3 ([@B4]). The current analysis found six phosphopeptides for PKD3, and another four whose sequence can be assigned to either PKD3 or PKD1. In addition, the data shows that there was no change in the SILAC ratio for PKD3 phosphosites in PKD2 deficient CTLs ([Table III](#TIII){ref-type="table"}). Thus, the loss of PKD2 catalytic function in CTLs is not compensated by increased expression or activity of other PKD isoforms.

###### PKD2 and PKD3 phosphosites. List of phosphosites derived from PKD isoforms detected in CTL phosphoproteome, presented as gene name, modified position (Mod. Pos.), sequence window (Seq. window) and SILAC ratio KO/WT (KO/WT ratio, averaged value of the three biological replicates)

  Gene name       Mod. Pos.   Seq. window           KO/WT ratio
  --------------- ----------- --------------------- -------------
  **PKD2**                                          
  *Prkd2*         S197        ARKRRL**S**STSLAS     0.67
                  S198        RKRRLS**S**TSLASG     0.43
                  S200        RRLSST**S**LASGHS     0.48
                  S211        HSVRLG**S**SESLPC     0.36
                  S212        SVRLGS**S**ESLPCT     0.63
                  S214        RLGSSE**S**LPCTAE     0.18
                  S711        EKSFRR**S**VVGTPA     0.11
                  S873        GLAERI**S**IL\_\_\_   0.06
  ***PKD3***                                        
  *Prkd3*         S31         APSPCS**S**PKTGLS     1.37
                  S27         AVLPAP**S**PCSSPK     1.26
                  S30         PAPSPC**S**SPKTGL     1.17
                  S213        VRKRRL**S**NVSLPG     1.06
                  S216        RRLSNV**S**LPGPGL     1.06
                  S252        PSKRIP**S**WSGRPI     0.96
  *Prkd3;Prkd1*   S391        ETVKTI**S**PSTSNN     1.07
                  S395        TISPST**S**NNIPLM     0.97
                  S730        RIIGEK**S**FRRSVV     0.79
                  S734        EKSFRR**S**VVGTPA     0.79

The PKD2 deficient mice used in the present study were generated by a retrovirus-based gene-trap technique, where the "gene-trap" insertion within the *Prkd2* locus was mapped to exon 15 encoding from amino acid 658 of PKD2 ([@B4]). PKD2 antibodies raised against the C-terminal portion of the protein (exons 16--18) have thus confirmed the loss of PKD catalytic activity in PKD2 "gene-trap" mice ([@B4]), but the possibility that a truncated N-terminal noncatalytic fragment of PKD2 protein might be expressed in the PKD2 "gene-trap" T cells has not been considered. The present data also show that phosphosites from the C terminus of PKD2 were down-regulated by more than 14-fold in the PKD2 "gene-trap," indicating that they are absent ([Table III](#TIII){ref-type="table"}). However, phosphosites derived from the N terminus of PKD2 (S197, S198, S200, S211, and S212) showed a two- to threefold decrease in expression in PKD2 gene trap CTLs. These data argue that PKD2 "gene-trap" T cells still express a low level of a residual N-terminal fragment of PKD2 and confirm that they lack the PKD2 catalytic domain.

As mentioned above, CTL effector function is maintained by the integration of signals emanating from the TCR and the IL-2R. The SILAC ratio of wild-type and PKD2 deficient cells comparison displayed a normal distribution ([Fig. 2](#F2){ref-type="fig"}*A*), suggesting that deletion of PKD2 did not skew the CTL phosphoproteome. In particular, there was not a general decrease in TCR regulated phosphorylations in PKD2 null cells. For instance, TCR triggering elevates intracellular calcium levels and induces calcium/calcineurin-regulated dephosphorylation of the transcription factor Nuclear Factor of Activated T cells c2 isoform (NFATc2) ([@B17]). PKD2 loss had no impact on NFATc2 phosphorylation ([Table IV](#TIV){ref-type="table"}). There was also no evidence for loss of TCR mediated phosphorylation of the microtubule stabilizing protein Stathmin (*Stmn1*) on residues that are phosphorylated by Calcium/Calmodulin dependent kinase IV ([Table IV](#TIV){ref-type="table"}). Moreover, triggering of the TCR phosphorylates AMPKα1 on Thr172 via a \[Ca^2+^\]i-CaMKK pathway and AMPK Thr172 phosphorylation was normal in PKD2 null T cells (corresponding to *Prkaa1*-Thr183 in our data set, [Table IV](#TIV){ref-type="table"}). It was also notable that the phosphorylation and activity of Erk1 and 2 was not influenced by PKD2 loss (*Mapk3* and *Mapk1*, respectively, [Table IV](#TIV){ref-type="table"}). IL-2R signaling in CTLs induces high levels of active Akt and we noted normal levels of phosphorylated Akt substrate sites Ser253/Ser252 in Foxo1/3 respectively, indicating that Akt activity was normal in PKD2 null CTL ([Table V](#TV){ref-type="table"}). Moreover, IL-2 controls the tyrosine and serine phosphorylation of the transcription factors STAT3, STAT5a, and STAT5b in T cells ([@B38], [@B39]). These transcription factors were normally tyrosine and serine phosphorylated in PKD2 null CTL ([Table V](#TV){ref-type="table"}). Collectively, data in [Table IV](#TIV){ref-type="table"} and V show that many CTL signaling pathways function normally in the absence of PKD2 catalytic function.

![**Impact of loss of PKD2 in the CTL phosphoproteome.** *A*, Histogram shows the SILAC ratio distribution of the data set, using the averaged SILAC ratio of the three biological replicates (PKD2 knockout *versus* wild-type, AVG KO/WT, log~2~ value). *B*, Graph shows SILAC ratio distribution (AVG KO/WT, log~2~ value) plotted against the signal intensity (sum of intensities of the three biological replicates, log~10~) for all identified phosphopeptides. Dark dots and inset numbers indicate phosphosites (p-sites) with a z-score of 2 (1.8-fold change). *C*, Graph represents the statistical significance (*p value*) of the biological processes overrepresented among the proteins with down-regulated and up-regulated phosphosites in PKD2 deficient CTLs. Inset numbers indicate number of proteins in each group. *D*, Phosphosites derived from CD5 (*Cd5*), presented as gene name, modified position (Mod. Pos.) and SILAC ratio KO/WT (KO/WT ratio, averaged value of the three biological replicates). *E*, Flow cytometry analysis of CD5 cell surface expression in P14 wild-type (P14-PKD2-WT) and PKD2 knockout (P14-PKD2-KO) CTLs. *F*, Phosphosites derived from Cofilin (*Cfl1*), presented as gene name, modified position (Mod. Pos.) and SILAC ratio KO/WT (KO/WT ratio, averaged value of the three biological replicates). *G*, Western blot analysis of wild-type and PKD2 knockout (WT and PKD2-KO) CTLs after 5 min of antigen receptor stimulation (TCR), using anti-phospho-Cofilin-Ser3 and anti-Cofilin antibodies. *H*, Graph shows SILAC ratio distribution plotted as in 2*B* for all identified phosphopeptides. Dark dots and inset number indicate phosphosites with at least 1.8-fold down-regulation that contain a PKD2 consensus motif (PKD2 motif). *I*, Frequency of PKD2 consensus motifs among all, up- and down-regulated phosphopeptides. Asterisks indicate significance of PKD2 motif enrichment (\*\*\* = *p* \< 0.0001, Chi-square test).](zjw0121449220002){#F2}

###### T-cell receptor regulated phosphosites. Selected phosphosites known to change phosphorylation status after TCR stimulation, presented as gene name, modified position (Mod. Pos.) and SILAC ratio KO/WT (KO/WT ratio, averaged value of the three biological replicates)

  Gene name   Mod. Pos.   KO/WT ratio
  ----------- ----------- -------------
  *Nfatc2*    S136        0.99
              S238        0.74
              S270        0.50
              S365        1.40
              S369        1.53
              S757        0.98
  *Stmn1*     S16         0.90
              S25         0.92
              S38         0.82
              S63         0.93
  *Prkaa1*    T183        1.04
  *Mapk3*     T203        1.18
  *Mapk1*     T179        1.00
              T183        0.99

###### Interleukin 2 regulated phosphosites. Selected phosphosites known to change phosphorylation status after IL-2 stimulation, presented as in [Table IV](#TIV){ref-type="table"}

  Gene name   Mod. Pos.   KO/WT ratio
  ----------- ----------- -------------
  *Stat3*     Y705        1.73
              S727        1.33
  *Stat5a*    Y694        0.88
              S779        1.24
  *Stat5b*    Y699        0.90
  *Akt1*      S473        0.82
  *Akt2*      S474        0.96
  *Foxo1*     S253        0.98
  *Foxo3*     S252        0.97

#### PKD2 Regulated Phosphorylations in CTL

There was some impact of PKD2 loss on the CTL phosphoproteome. Hence, of the 15,871 unique phosphosites identified and quantified in CTLs, 450 phosphosites on 281 distinct proteins were down-regulated and 300 phosphosites on 196 proteins were up-regulated in PKD2 null CTLs ([Fig. 2](#F2){ref-type="fig"}*B*). The threshold for change was set to a z-core of 2 for phosphorylation ratios in PKD2 null *versus* wild-type CTLs, using the averaged value of the three biological replicates (1.8-fold change). We discarded phosphorylation events that displayed an inconsistent trend in regulation among the three biological replicates (*i.e.* down-regulated in one replicate and up-regulated in another). Based on this threshold, the data showed that PKD2 directly and indirectly regulates about 5% of the phosphorylations of cytotoxic T cells, on proteins that are mainly involved in transcription, chromosome reorganization and more importantly in the context of cytotoxic T cells, in leukocyte activation and hemopoiesis ([Fig. 2](#F2){ref-type="fig"}*C*).

Among the down-regulated sites implicated in leukocyte activation we found five phosphosites derived from CD5 ([Fig. 2](#F2){ref-type="fig"}*D*), a cell surface glycoprotein whose expression is normally increased after activation in T cells ([@B40]). This could reflect loss of CD5 phosphorylation or loss of CD5 expression. In this respect we have established that PKD2 controls expression of CD5 during T-cell development ([@B15]) but its role in controlling CD5 expression in peripheral T cells is unknown. Accordingly, we used flow cytometry to examine if CD5 expression was impaired in PKD2 deficient CTLs. Data in [Fig. 2](#F2){ref-type="fig"}*E* show that PKD2 deficient CTLs express lower levels of CD5 than their wild-type counterparts.

We also found two down-regulated phosphosites derived from the F-actin severing protein Cofilin, Ser3, and Ser41, in the TCR activated PKD2 null CTL ([Fig. 2](#F2){ref-type="fig"}*F*). This result was initially surprising as previous studies have shown that TCR triggering, which activates PKD2, normally down-regulates Cofilin-Ser3 phosphorylation ([@B17]). Indeed, Western blot experiments confirmed that TCR triggering reduces Cofilin-Ser3 phosphorylation in CTLs ([Fig. 2](#F2){ref-type="fig"}*G*). Nevertheless, there was strikingly less phosphorylated Cofilin-Ser3 in the both nonstimulated and TCR stimulated PKD2 null T cells compared with wild-type cells ([Fig. 2](#F2){ref-type="fig"}*G*). These data orthogonally validated the reduced Cofilin-Ser3 phosphorylation in the TCR activated PKD2 null T cells observed in the mass spectrometry experiments ([Fig. 2](#F2){ref-type="fig"}*F*, *G*). The reduced Cofilin phosphorylation in PKD2 null T cells argues that PKD might control the activity of kinase pathways upstream Cofilin phosphorylation. In this respect, previous studies have reported a PKD requirement for the phosphorylation of Ser3 on Cofilin via PKD activation of PAK4/LIMK ([@B41], [@B42]).

To search for PKD2 substrate candidates within the data set we used the following criteria: the SILAC ratio must be down-regulated in the PKD2 null cells, and the sequence of the down-regulated phosphosite must correspond to a PKD2 consensus motif. The consensus sequence for PKD2 phosphorylation described in the literature is (L/V/I)x(R/K)xx(S\*/T\*) ([@B43][@B44]--[@B45]). In addition to the described consensus site, PKD2 has an auto-phosphorylation site at residue Ser873 (Ser916 in PKD1) ([@B37]). This PKD2 autophosphorylation motif has slightly modified sequence compared with the conventional motif, (L/I)xx(R/K)x(S\*/T\*), but because it is a well described substrate for PKD2 we have included this sequence in our search for PKD2 phosphorylation sites. The analysis of the whole data set determined that among the 15,871 phosphosites found in our study, 940 contained a consensus motif for PKD2 phosphorylation (6% of the data set) ([supplemental Table S1](http://www.mcponline.org/cgi/content/full/M113.037242/DC1)). Strikingly, 73 out of the 450 phosphosites (16%) with decreased phosphorylation in PKD2 deficient CTLs had a PKD2 consensus motif, whereas only 26 out of the 300 phosphosites (9%) with increased phosphorylation matched the PKD2 consensus motif ([Fig. 2](#F2){ref-type="fig"}*H*). Thus among the down-regulated phosphosites in PKD2 knockout CTLs, we had a significant enrichment of phosphosites containing a consensus phosphorylation site for PKD2 (*p* \< 0.0001, [Fig. 2](#F2){ref-type="fig"}*I*). Detailed information about modified position and ratios of the 73 phosphosites on 69 distinct proteins down-regulated in our data set that had a PKD2 consensus motif can be found in [supplemental Table S4](http://www.mcponline.org/cgi/content/full/M113.037242/DC1). It was notable that 377 of the 450 phosphosites with decreased phosphorylation in PKD2 deficient CTLs, including Cofilin1-Ser3 ([Fig. 2](#F2){ref-type="fig"}*E*), did not have a consensus PKD2 site and hence are unlikely to be directly phosphorylated by PKD2 ([Fig. 2](#F2){ref-type="fig"}*B*, [2](#F2){ref-type="fig"}*F*). In addition, loss of PKD2 increased the phosphorylation of 300 phosphosites ([Fig. 2](#F2){ref-type="fig"}*B*) and this is clearly an indirect consequence of PKD2 loss.

[Table VI](#TVI){ref-type="table"} lists the 69 proteins phosphorylated on a PKD2 consensus sequence whose phosphorylation was decreased in PKD2 null T cells. It also lists the biological function ascribed to these proteins. The decreased phosphorylation of these proteins in PKD2 null cells could reflect that they are direct substrates for PKD2. However, it is possible that the expression of the protein is decreased. To attempt discriminate between these possibilities, we analyzed all the phosphosites found in our study for the proteins presented in [Table VI](#TVI){ref-type="table"}. For 41 proteins we could find evidence that although they had lost phosphorylation on PKD consensus sequences there were other phosphorylation sites that were unchanged, indicating that the protein expression was not decreased. For 22 proteins only one to two phosphosites were found and hence we cannot make any conclusion about their expression. However, for another four proteins, HDAC7, Osbl3, Sgk223, and Specc1, there was decreased phosphorylation of all detected peptides derived from these proteins ([supplemental Table S1](http://www.mcponline.org/cgi/content/full/M113.037242/DC1)). This could indicate that there is lower expression of these proteins in PKD2 deficient CTLs. This second group included histone deacetylase HDAC7 ([Table VI](#TVI){ref-type="table"}), which is a well characterized PKD substrate in many cells including B cells ([@B12], [@B46]). Moreover, in CTLs, HDAC7 phosphorylation on PKD consensus sites is essential for HDAC7 nuclear exclusion ([@B17]). HDAC7 is thus a very strong candidate for a PKD2 substrate in CTLs. However, [Fig. 3](#F3){ref-type="fig"}*A* shows that the loss HDAC7 phosphorylation in PKD2 null CTLs occurred on multiple sites and was not restricted to the PKD substrate sequences Ser156 and Ser182 ([@B47], [@B48]). We therefore explored the possibility that PKD2 knockout CTLs may have decreased expression of HDAC7. The Western blot in [Fig. 3](#F3){ref-type="fig"}*B* addresses this question and shows that PKD2 knockout CTLs express lower levels of HDAC7 compared with wild-type CTLs. The decrease in HDAC7 phosphorylation in PKD2 null CTL thus reflects that these cells have reduced expression of this molecule. In this respect, nonphosphorylated HDAC7 would accumulate in the nucleus whereas phosphorylated HDAC7 is in the cytosol ([@B17]). Confocal microscopy comparing the intracellular location of HDAC7 in wild-type and PKD2 deficient CTLs clearly showed that HDAC7 localization is mainly cytosolic in both wild-type and PKD2-deficient CTLs ([Fig. 3](#F3){ref-type="fig"}*C*). HDAC7 phosphorylation on PKD consensus sites is also essential for CTL to express the IL-2Ralpha chain (CD25) ([@B17]). [Fig. 3](#F3){ref-type="fig"}*D* shows that PKD2 deficient cells express normal levels of CD25. These data collectively argue that HDAC7 is not a PKD2 substrate in cytotoxic T cells.

###### Functional annotation of PKD2 substrate candidates. 73 PKD2 substrate candidates involved in the indicated cellular functions were categorized based on available literature

  Intracellular transport   Lymphocyte signaling                       
  ------------------------- ---------------------- --------- --------- ----------
  Arhgap11a                 Arhgef2                Akap10    Dennd5a   Casp8ap2
  Arhgef2                   Arpc1b                 Arl14ep   Lrmp      Cbl
  Kifap3                    Lpp                    Cbl       Osbpl3    Hsh2d
  Rin3                      Map4                   Hip1r     Ssr3      Ikbke
  Tsc2                      Ndrg1                  Kifap3              Inpp4b
                            Ospl3                  Ndrg1               Ndrg1
                            Plec                   Reps1               Plekha2
                            Rin3                   Snx2                Prrc2a
                            Tjp3                   Snx9                Ptpn22
                            Vim                    Tbc1d5              Sgk223
                            Wnk1                   Ube2o               Tsc2
                                                   Vps26b              

  Gene expression   Other functions                     
  ----------------- ----------------- -------- -------- --------
  Arid4b            Casp8ap2          Bud13    Cbl      Ccdc92
  Arid5b            Lpp               Farsa    Dcaf5    Dmwd
  Hdac5             Lrrfip1           Nup214   Rnf213   Dnajc8
  Hdac7             Nfatc3            Pcbp1    Ube2o    Fam76b
  Kansl3            Pola2             Phax              Specc1
  Kdm2a             Polk              Rpl19             
  Setdb1            Rdbp              Sugp2             
  Sfr1              Supt16h                             
                    Trim28                              
                    Ylpm1                               
                    Znf280d                             
                    Zfp687                              

![**Analysis of HDAC7 phosphorylation, expression and function in PKD2 deficient CTLs.** *A*, Phosphosites derived from HDAC7 (*Hdac7*), presented as gene name, modified position (Mod. Pos.) and SILAC ratio KO/WT (KO/WT ratio, averaged value of the three biological replicates). *B*, Western blot analysis of three sets of wild-type and PKD2 knockout (WT and PKD2-KO) CTLs using an anti-HDAC7 antibody. Anti-Erk1 antibody was used as a control of equal loading. *C*, Microscopy analysis of the subcellular distribution of GFP-HDAC7 in retrovirally transduced P14 wild-type (P14-PKD2-WT) and PKD2 knockout (P14-PKD2-KO) CTLs. Original magnification, ×100. *D*, Flow cytometry analysis of CD25 cell surface expression in P14 wild-type (P14-PKD2-WT) and PKD2 knockout (P14-PKD2-KO) CTLs.](zjw0121449220003){#F3}

The data presented for HDAC7 is thus a good demonstration of how decreased phosphorylation of a protein in a particular cell may be because of the fact its expression is decreased. Nevertheless, in the current data set there were at least 41 proteins that had decreased phosphorylation on PKD substrate sequences yet phosphorylations on other sites were unchanged, making these strong candidates to be PKD2 substrates ([Table VII](#TVII){ref-type="table"}). Six of these proteins, Hip1r, Map4, Rdbp, Ssr3, Snx2, and Pcbp1, have been shown to be *in vitro* substrates for PKD1 ([@B19]) ([Tables VI](#TVI){ref-type="table"} and [VII](#TVII){ref-type="table"}). We also identified Rin3 (Ras and Rab interactor 3) as a PKD2 substrate ([Tables VI](#TVI){ref-type="table"} and [VII](#TVII){ref-type="table"}) and previous studies have identified Rin1 as a PKD1 substrate in fibroblasts ([@B49]). It was, however, important that our studies identified novel PKD2 substrate candidates in CTLs such the E3 ubiquitin ligase c-Cbl (*Cbl*) ([@B50]), the Lysine (K)-specific demethylase 2a (*Kdm2a*) ([@B51]), the transcription factor NFAT3 ([@B52]) and the Phosphorylated adaptor for RNA export (*Phax*), a regulator of U snRNA nuclear export ([@B53]).

###### PKD2 substrate candidates phosphosites. List of phosphosites from selected PKD2 substrate candidates, presented as gene name, protein name, modified position (Mod. Pos.) and SILAC ratio KO/WT (KO/WT ratio, averaged value of the three biological replicates)

  Gene name     Protein name                                                Mod. Pos.   KO/WT Ratio
  ------------- ----------------------------------------------------------- ----------- -------------
  *Akap10*      A-kinase anchor protein 10, mitochondrial                   S257        0.47
  *Arhgap11a*   Rho GTPase-activating protein 11A                           S847        0.51
  *Arhgef2*     Rho guanine nucleotide exchange factor 2                    S718        0.57
  *Arid4b*      AT-rich interactive domain-containing protein 4B            S473        0.42
  *Arid5b*      AT-rich interactive domain-containing protein 5B            S1002       0.20
  *Bud13*       BUD13 homolog                                               S18         0.39
  *Casp8ap2*    CASP8-associated protein 2                                  S1220       0.48
  *Cbl*         E3 ubiquitin-protein ligase CBL                             S617        0.57
  *Ccdc92*      Coiled-coil domain-containing protein 92                    S308        0.40
  *Dcaf5*       DDB1- and CUL4-associated factor 5                          S790        0.11
  *Dennd5a*     DENN domain-containing protein 5A                           S193        0.47
  *Dmwd*        Dystrophia myotonica WD repeat-containing protein           T453        0.38
  *Fam76b*      Protein FAM76B                                              S227        0.18
  *Hip1r*       Huntingtin-interacting protein 1-related protein            S1045       0.13
  *Inpp4b*      Type II inositol 3,4-bisphosphate 4-phosphatase             S470        0.23
  *Kansl3*      KAT8 regulatory NSL complex subunit 3                       S631        0.43
  *Kdm2a*       Lysine-specific demethylase 2A                              S422        0.29
  *Lrmp*        Lymphoid-restricted membrane protein                        S346        0.55
  *Lrrfip1*     Leucine-rich repeat flightless-interacting protein 1        S284        0.56
  *Map4*        Microtubule-associated protein 4                            S973        0.48
  *Nfatc3*      Nuclear factor of activated T-cells, cytoplasmic 3          S416        0.54
  *Nup214*      Nuclear pore complex protein Nup214                         S1029       0.37
  *Pcbp1*       Poly(rC)-binding protein 1                                  S246        0.52
  *Phax*        Phosphorylated adapter RNA export protein                   S155        0.41
  *Plekha2*     Pleckstrin homology domain-containing family A member 2     S349        0.45
  *Pola2*       DNA polymerase alpha subunit B                              S126        0.38
  *Prrc2a*      Protein PRRC2A                                              S166        0.44
  *Ptpn22*      Tyrosine-protein phosphatase non-receptor type 22           S452        0.52
  *Rdbp*        Negative elongation factor E                                S37         0.21
  *Reps1*       RalBP1-associated Eps domain-containing protein 1           S475        0.50
  *Rin3*        Ras and Rab interactor 3                                    S389        0.39
  *Rnf213*      E3 ubiquitin-protein ligase RNF213                          S4603       0.27
  *Sfr1*        Swi5-dependent recombination DNA repair protein 1 homolog   S139        0.22
  *Snx2*        Sorting nexin-2                                             S226        0.38
  *Supt16h*     FACT complex subunit SPT16                                  S650        0.57
  *Tbc1d5*      TBC1 domain family member 5                                 S546        0.45
  *Tsc2*        Isoform E of Tuberin                                        S1254       0.52
  *Ube2o*       Ubiquitin-conjugating enzyme E2 O                           S394        0.40
  *Vps26b*      Vacuolar protein sorting-associated protein 26B             S304        0.40
  *Wnk1*        Serine/threonine-protein kinase WNK1                        S2625       0.49
  *Znf687*      Zinc finger protein 687                                     S1118       0.18
  *Znf687*      Zinc finger protein 687                                     S495        0.43
  *Znf687*      Zinc finger protein 687                                     S351        0.54

DISCUSSION
==========

The present study explores the phosphoproteome of antigen receptor activated cytotoxic T lymphocytes and identifies 15,871 unique phosphorylation sites on 3505 distinct proteins in this critical lymphocyte population. This is a unique data set about the kinase-substrate signaling networks in CTL that allows new insights about the repertoire of protein kinases that are expressed and active in T cells. One new vision derived from this work is that the CTL phosphoproteome was overrepresented by proteins that regulate macromolecular catabolic processes, notably proteins that control the ubiquitylation and sumoylation. In this respect, the reversible ubiquitin or sumo modification of proteins is critical for intracellular signal transduction pathways ([@B54], [@B55]). Moreover, it has been recognized for several years that cross talk between phosphorylation and ubiquitylation/sumoylation signaling occurs ([@B56], [@B57]). For example, phosphorylation of various E3 ligases can either positively or negatively regulate their deubiquitylation activity ([@B56]). The phosphorylation of a protein can create a docking site for a particular E3 ligase whereas in other cases, phosphorylation controls the intracellular localization of E3 ligases and their substrates ([@B56]). The full extent of the cross talk between protein phosphorylation and ubiquitylation is not understood in any cell system. However, the over-representation in the CTL phosphoproteome of molecules linked to the control of ubiquitylation and sumoylation signaling is a striking indication that the intersection between different post-transcriptional modifications may be critical to control CTL function.

The study also presents an exhaustive analysis of the impact of the loss of a single kinase, PKD2, in CTLs using an unbiased phosphoproteomic approach. This global analysis allows the characterization of direct and indirect PKD2-regulated phosphorylation events. CTL express a minimum of 200 kinases yet the loss of a single kinase can have complex direct and indirect effects on the phosphoproteome. A single kinase PKD2 thus directly and indirectly regulates about 5% of CTL phosphorylations. Proteins identified as PKD2 substrates in CTLs include proteins involved in two distinct biological functions: regulation of intracellular protein trafficking and control of different aspects of gene expression. In the context of vesicular trafficking, the proteins phosphorylated by PKD2 in CTLs include a number of Rab GTPases regulators such as Akap10 ([@B58]), Tbc1d5 ([@B59]), and Rin3 ([@B60]), or Sorting nexin 2 (Snx2) ([@B59]), which contains a phosphoinositide binding domain. Notably, the relocalization of intracellular vesicles containing signaling molecules has been shown to be required for antigen receptor signal propagation in T cells ([@B61], [@B62]). Future experiments will determine if PKD2-regulated phosphorylations influence the amplitude, location, and duration of T-cell signaling by controlling intracellular vesicle trafficking. Interestingly, among the PKD2 substrate candidates we also find GEF-H1 (*Arhgef2*), a microtubule-associated guanine nucleotide exchange factor whose function has been recently shown to be crucial for antiviral host defenses ([@B63]). In the context of phosphorylation and ubiquitylation crosstalk mentioned above, our study identified the E2 ubiquitin conjugating enzyme Ube2o which has a crucial role in endosomal protein trafficking ([@B64]) as novel PKD2 substrate in CTLs. Moreover the identification of the E3 ligase c-Cbl as a PKD2 substrate is also interesting, because c-Cbl is known to regulate the function and intracellular trafficking of several molecules implicated in antigen receptor signaling ([@B50]). Future studies into the role of PKD2 in regulating endosomal protein trafficking in CTLs may thus be interest.

Previous studies have shown that PKD2 has a critical role to control the T-cell transcriptional program. Antigen stimulation in CD8 T cells induces changes in the expression levels of ∼2600 annotated genes and PKD2 both positively and negatively regulates expression of 5% this transcriptional program ([@B5]). Here we have identified PKD2 substrate candidates implicated in regulation of transcription and translation such as the Lysine (K)-specific demethylase 2a (Kdm2a) ([@B51]), the transcription factor NFAT3 ([@B52]) and Phax ([@B53]), a protein that controls mRNA export from the nucleus. However, the diversity of the PKD2 controlled phosphoproteome identified herein affords an explanation for the broad role of PKD2 as a regulator of the T-cell transcriptional program. Thus, there is no evidence for a simple linear pathway of phosphorylation of a single substrate that explains PKD2 action. Rather, the impact of PKD2 loss will thus result from a complex interplay between the direct and indirect effects of PKD2 loss on the phosphoproteome that are exposed by the present work.

A small number of the PKD2 substrates identified herein have been shown to be substrates for PKD family kinases in other cell lineages (Hip1r, Map4, Rdbp, Ssr3, Snx2, and Pcbp1). However, it is of equal importance to note that some of the key PKD substrates identified in experiments in fibroblasts, endothelial, and epithelial cells are not substrates in T cells. HDAC7 is thus a PKD substrate in many cells but not in CTLs, the protein phosphatase Slingshot (SSH1) is phosphorylated on Ser929 by PKD in HeLa and breast adenocarcinoma cell lines ([@B6], [@B7]) whereas the present data set revealed that SSH1 was phosphorylated on Ser929 in CTLs but this phosphorylation was not reduced on PKD2 null CTLs ([supplemental Table S1](http://www.mcponline.org/cgi/content/full/M113.037242/DC1)). In the context of intracellular protein transport and Golgi function, other well described PKD substrates are the phosphatidylinositol-4 kinase III beta; a regulator of Golgi vesicle fission and protein secretion ([@B9]) and the lipid and sterol transfer proteins CERT and OSBP ([@B10], [@B11]). The present data identified eight unique phosphosites on phosphatidylinositol-4 kinase III beta (*Pi4kb*) including the Ser294, the PKD site previously characterized by Hausser and colleagues in fibroblast ([@B9]). We found that there was no reproducible loss of the phosphorylation of Phosphatidylinositol-4 kinase III beta in PKD2 null cells. Similarly, the ceramide transfer protein CERT (*Col4a3bp*) has been shown to be phosphorylated on Ser132 by PKD, thereby reducing its ceramide transfer activity and placing PKD as a regulator of lipid homeostasis. The phosphorylation of CERT of Ser132 was not reproducibly lost in PKD2 null CTLs making this an unlikely PKD2 substrate in CTLs.

Collectively, the data presented here show that PKD family kinases have both common and unique functions in different cell lineages. One explanation for this variability in substrates for different PKD isoforms could be that PKDs show cell lineage specific patterns of intracellular localization. For example in HEK293 and Hela cells PKD isoforms localize to the trans-Golgi network, where PKD phosphorylates substrates such as phosphatidylinositol-4 kinase III beta ([@B9]), CERT, and OSBP ([@B10], [@B11]). PKD1 has been also shown to be recruited to the lamellipodium in HEK293 cells and pancreatic tumor cell lines, where PKD phosphorylates substrates such as SSH1 ([@B6], [@B7]), cortactin ([@B65]), or Rin1 ([@B8]). In contrast, active PKD is mainly cytosolic in T cells ([@B2]). PKD is briefly recruited to the plasma membrane after antigen receptor stimulation but rapidly returns to the cytosol where it remains active ([@B2]). Thus, the cytosolic localization of PKD2 in T cells may prevent the access to substrates in particular cell compartments such as the Golgi network or the plasma membrane.
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